Literature DB >> 10602746

Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria.

S K Spangler1, S Bajaksouzian, M R Jacobs, P C Appelbaum.   

Abstract

The postantibiotic effect (PAE) (10x the MIC) and the postantibiotic sub-MIC effects (0.125, 0.25, and 0.5x the MIC) were determined for six compounds against 12 strains. Measurable PAEs ranged between 0 and 1.8 h for grepafloxacin, 0 and 2.2 h for ciprofloxacin, 0 and 3. 1 h for levofloxacin, 0 and 2.2 h for sparfloxacin, 0 and 2.4 h for amoxicillin-clavulanate and 0 and 4.8 h for clarithromycin. Reexposure to subinhibitory concentrations increased the PAEs against some strains.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10602746      PMCID： PMC89651          DOI： 10.1128/AAC.44.1.186-189.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A Brueggemann; H P Holley; A M Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.

Authors:  S K Spangler; G Lin; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

4.  In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.

Authors:  F Marco; R N Jones; D J Hoban; A C Pignatari; N Yamane; R Frei
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

5.  Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.

Authors:  G V Doern; A B Brueggemann; G Pierce; H P Holley; A Rauch
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.

Authors:  P J Cook; J M Andrews; R Wise; D Honeybourne; H Moudgil
Journal:  J Antimicrob Chemother       Date:  1995-02       Impact factor: 5.790

7.  Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

Authors:  I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

8.  In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.

Authors:  T Imada; S Miyazaki; M Nishida; K Yamaguchi; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 9.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

10.  Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin.

Authors:  J Child; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191
View more
  7 in total

1.  Translating slow-binding inhibition kinetics into cellular and in vivo effects.

Authors:  Grant K Walkup; Zhiping You; Philip L Ross; Eleanor K H Allen; Fereidoon Daryaee; Michael R Hale; John O'Donnell; David E Ehmann; Virna J A Schuck; Ed T Buurman; Allison L Choy; Laurel Hajec; Kerry Murphy-Benenato; Valerie Marone; Sara A Patey; Lena A Grosser; Michele Johnstone; Stephen G Walker; Peter J Tonge; Stewart L Fisher
Journal:  Nat Chem Biol       Date:  2015-04-20       Impact factor: 15.040

2.  In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Authors:  Michael D Huband; Patricia A Bradford; Linda G Otterson; Gregory S Basarab; Amy C Kutschke; Robert A Giacobbe; Sara A Patey; Richard A Alm; Michele R Johnstone; Marie E Potter; Paul F Miller; John P Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

Review 3.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.

Authors:  Inga Odenholt; Elisabeth Löwdin; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 5.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit.

Authors:  Berna Ozbek Celik; Emel Mataraci-Kara; Mesut Yilmaz
Journal:  Biomed Res Int       Date:  2014-10-28       Impact factor: 3.411

7.  Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.

Authors:  Myriam V Valenzuela; Mirian Domenech; Patricia Mateos-Martínez; Fernando González-Camacho; Adela G de la Campa; Maria Teresa García
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.